Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 31060523)

  • 1. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
    BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker Assessment of HR Deficiency, Tumor
    Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
    Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
    Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
    Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
    [No Abstract]   [Full Text] [Related]  

  • 4. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
    Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
    Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
    J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
    Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
    Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
    Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
    Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
    Feng Z; Shao D; Cai Y; Bi R; Ju X; Chen D; Song C; Chen X; Li J; An N; Li Y; Zhou Q; Xiu Z; Zhu S; Wu X; Wen H
    J Ovarian Res; 2023 Mar; 16(1):53. PubMed ID: 36922847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
    Pennington KP; Walsh T; Harrell MI; Lee MK; Pennil CC; Rendi MH; Thornton A; Norquist BM; Casadei S; Nord AS; Agnew KJ; Pritchard CC; Scroggins S; Garcia RL; King MC; Swisher EM
    Clin Cancer Res; 2014 Feb; 20(3):764-75. PubMed ID: 24240112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
    Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
    J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic lethality between CCNE1 amplification and loss of BRCA1.
    Etemadmoghadam D; Weir BA; Au-Yeung G; Alsop K; Mitchell G; George J; ; Davis S; D'Andrea AD; Simpson K; Hahn WC; Bowtell DD
    Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19489-94. PubMed ID: 24218601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
    Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
    Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
    J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
    Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
    BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.
    Etemadmoghadam D; deFazio A; Beroukhim R; Mermel C; George J; Getz G; Tothill R; Okamoto A; Raeder MB; Harnett P; Lade S; Akslen LA; Tinker AV; Locandro B; Alsop K; Chiew YE; Traficante N; Fereday S; Johnson D; Fox S; Sellers W; Urashima M; Salvesen HB; Meyerson M; Bowtell D;
    Clin Cancer Res; 2009 Feb; 15(4):1417-27. PubMed ID: 19193619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable response to palbociclib and letrozole in ovarian cancer with
    Frisone D; Charrier M; Clement S; Christinat Y; Thouvenin L; Homicsko K; Michielin O; Bodmer A; Chappuis PO; McKee TA; Tsantoulis P
    Cancer Biol Ther; 2020; 21(3):197-202. PubMed ID: 31709901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.